Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc. (NASDAQ: BYSI) generates a steady flow of news centered on the clinical and regulatory progress of its lead asset, Plinabulin, and on its corporate and financing activities. As a clinical-stage biopharmaceutical company focused on cancer, BeyondSpring’s updates often highlight new data from phase 2 and phase 3 trials in non-small cell lung cancer (NSCLC) and other tumor types, as well as mechanistic findings related to Plinabulin’s dendritic cell maturation and immune-modulating properties.
News releases frequently cover results from major oncology conferences and journals. Examples include presentations at the American Society of Clinical Oncology (ASCO), the IASLC/ASCO North America Conference on Lung Cancer (NACLC), the Society for Immunotherapy of Cancer (SITC), Immuno-Oncology 360°, and ESMO Asia, along with peer-reviewed publications in outlets such as Lancet Respiratory Medicine and Med (Cell Press). These communications describe outcomes from the DUBLIN‑3 phase 3 trial, the 303 and 302 phase 2 studies, and basket trials combining Plinabulin with checkpoint inhibitors, chemotherapy, and radiation.
Investors following BYSI news can also expect regular financial updates, including quarterly results, cash position, and operating expense trends, as well as 10‑K filing announcements. Corporate news items address equity financings, such as registered offerings of ordinary shares, and strategic transactions involving BeyondSpring’s equity stake in SEED Therapeutics, a targeted protein degradation company co-founded by BeyondSpring.
For market participants tracking oncology pipelines, the BYSI news stream provides insight into Plinabulin’s clinical performance, safety profile, biomarker research, and planned registrational strategies, including the company’s intention to advance confirmatory trials like DUBLIN‑4. Bookmarking the news page allows readers to monitor how new data, conference presentations, and SEC-referenced announcements may influence the development trajectory of Plinabulin and BeyondSpring’s broader strategy.
BeyondSpring (NASDAQ: BYSI) will present a poster at the AACR Annual Meeting 2026 in San Diego on April 21, 2026. The poster, titled Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates, is scheduled for 2:00–5:00 PM PT in Poster Section 8, Poster Board 16 (Poster 5597).
The presentation appears in the Immunology session category under "T Cell Engagers 2 / Antibody-Drug Conjugates 1" and lists Yingjuan June Lu and colleagues as presenters/authors.
BeyondSpring (NASDAQ:BYSI) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the SEC on March 25, 2026.
The filing includes the company’s audited consolidated financial statements and is available on the SEC website and the company’s investor site. Shareholders may request a free hard copy from Investor Relations.
BeyondSpring (NASDAQ:BYSI) reported 2025 year-end results highlighting Phase 3 success for plinabulin in EGFR wild-type NSCLC and strategic progress at SEED Therapeutics.
Key facts: DUBLIN-3 showed OS HR 0.72 (p=0.0078) with median OS +2.5 months, grade 4 neutropenia reduced to 5%, DUBLIN-4 confirmatory trial planned (NCT07361484), SEED initiated Phase 1a for ST-01156, completed $30M Series A-3, and company cash was $12.6M as of Dec 31, 2025.
BeyondSpring (NASDAQ: BYSI) will participate at the Immuno-Oncology 360° Conference in Boston, February 10-12, 2026. Dr. Lan Huang, Co-Founder, Chairman and CEO, will present on Plinabulin on February 11, 2026, 4:55–5:10 PM ET in the Sheraton Boston Grand Ballroom.
Presentation covers Plinabulin’s mechanism and translational strategy to enhance PD-1/PD-L1 blockade; slides will be posted afterward on the company’s Posters and Presentations webpage.
BeyondSpring (NASDAQ: BYSI) reported results from the Asian subset (n=488) of the global Phase 3 DUBLIN-3 trial evaluating plinabulin + docetaxel versus docetaxel in 2L/3L EGFR wild-type NSCLC presented at ESMO Asia 2025. In the Asian ITT cohort, combination therapy achieved median OS 10.8 vs 8.8 months (HR 0.81, p=0.0426). In the mechanism‑aligned non‑squamous subgroup the HR was 0.69 with a 3‑month median OS benefit (p=0.0064). The combo doubled 2‑ and 3‑year survival rates and markedly reduced docetaxel‑induced grade 4 neutropenia (DP 3.9% vs D 26.5%, p<0.0001), while maintaining favorable tolerability.
BeyondSpring (NASDAQ: BYSI) reported post-hoc DUBLIN-3 analyses showing that plinabulin + docetaxel improved outcomes versus docetaxel in non-squamous EGFR wild-type NSCLC patients after progression on anti-PD-(L)1 therapy.
Key metrics in the subset: median OS 15.8 vs 11.7 months (HR=0.55), PFS 5.6 vs 3.8 months (HR=0.67), ORR 18.2% vs 8.0%. Metastasis-free survival improved to 15.34 vs 7.7 months (HR=0.52, p=0.0012) and new brain metastasis incidence fell to 4.32% vs 7.83%. Safety signals included a reduction in grade 4 neutropenia (5.13% vs 33.58%, p<0.0001) and fewer exposure-adjusted grade 3/4 AEs (p=0.0235). BeyondSpring plans a global registrational Phase 3 DUBLIN-4 to confirm these findings.
BeyondSpring (NASDAQ: BYSI) reported Q3 2025 results and clinical/corporate milestones on Nov 12, 2025. Key clinical data: a Phase 2 investigator-initiated NSCLC cohort (n=47) showed DCR 85%, median PFS 7.0 months, ORR 18.2%, DOR 7.2 months, 12‑month OS 79% and 24‑month OS 66% (median OS not reached). Phase 1 data across eight cancer types showed DCR 54% and a GEF‑1 dependent DC maturation/M1 macrophage mechanism. Corporate: co‑founded SEED (BeyondSpring ~38% ownership) closed a $30M Series A‑3 and received FDA and China NMPA IND clearance for SEED’s RBM39 program; SEED was finalist for Prix Galien USA. Q3 finances: continuing ops R&D $1.0M, G&A $0.8M, net loss continuing ops $1.7M, cash $12.5M as of Sept 30, 2025. BeyondSpring currently reports SEED as discontinued operations and expects future SEED sales to reduce ownership to ~14%.
BeyondSpring (NASDAQ: BYSI) reported Q2 2025 financial results and significant clinical advances. The company's lead drug Plinabulin showed promising results in NSCLC patients who progressed after PD-1/L1 therapy, demonstrating 6.8 months median PFS and 18.2% ORR in combination with pembrolizumab and docetaxel.
A Med (Cell Press) publication highlighted Plinabulin's ability to activate dendritic cells across eight cancer types, achieving 23% ORR and 54% DCR in immunotherapy-resistant patients. Additionally, SEED Therapeutics, where BeyondSpring holds a 40% stake, received FDA IND clearance for its RBM39 degrader ST-01156 and appointed Dr. Bill Desmarais as CFO/CBO.
Q2 2025 financials showed a net loss of $1.9M from continuing operations, improved from $2.7M in Q2 2024, with $9.5M cash on hand as of June 30, 2025.
BeyondSpring (NASDAQ: BYSI) has published significant clinical results in Med (Cell Press) demonstrating the effectiveness of Plinabulin in combination with radiation and checkpoint inhibitors for cancer treatment. The study showed an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in patients who previously failed immune checkpoint inhibitor (ICI) therapy.
The research revealed that Plinabulin works through GEF-H1-dependent dendritic cell maturation, with particularly strong responses in non-small cell lung cancer, head and neck squamous cell carcinoma, and Hodgkin lymphoma. Notably, Hodgkin lymphoma patients demonstrated durable responses exceeding 19 months despite having undergone 12-16 prior lines of therapy.